Cargando…

High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege

BACKGROUND: Intratumoral injection of cyclic dinucleotide (CDN) agonists of the stimulator of interferon genes (STING) pathway engages innate immune activation and priming of adaptive immune effectors to foster local and distal tumor clearance. Despite proven therapeutic efficacy in preclinical mode...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ager, Casey R, Boda, Akash, Rajapakshe, Kimal, Lea, Spencer Thomas, Di Francesco, Maria Emilia, Jayaprakash, Priyamvada, Slay, Ravaen B, Morrow, Brittany, Prasad, Rishika, Dean, Meghan A, Duffy, Colm R, Coarfa, Cristian, Jones, Philip, Curran, Michael A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Oncolytic and Local Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330562/ https://www.ncbi.nlm.nih.gov/pubmed/34341132 http://dx.doi.org/10.1136/jitc-2021-003246

Ejemplares similares

Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation
por: Alshebremi, Mohammad, et al.
Publicado: (2023)

Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
por: Jiang, Xiaoyi, et al.
Publicado: (2022)

Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma
por: Wang-Bishop, Lihong, et al.
Publicado: (2020)

STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer
por: Lee, Seung Joon, et al.
Publicado: (2021)

Ectopic expression of cGAS in Salmonella typhimurium enhances STING-mediated IFN-β response in human macrophages and dendritic cells
por: Waanders, Lisette, et al.
Publicado: (2023)

STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation
por: Nakamura, Takashi, et al.
Publicado: (2021)

Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy
por: Alvarez, Maite, et al.
Publicado: (2021)

Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer
por: Shakfa, Noor, et al.
Publicado: (2023)

Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer
por: Monge, Cecilia, et al.
Publicado: (2023)

In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy
por: Cheng, Yinwen, et al.
Publicado: (2020)

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors
por: Siu, Lillian, et al.
Publicado: (2020)

Nanoemulsion adjuvantation strategy of tumor-associated antigen therapy rephrases mucosal and immunotherapeutic signatures following intranasal vaccination
por: Huang, Chung-Hsiung, et al.
Publicado: (2020)

Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication
por: Flores, Erica B, et al.
Publicado: (2020)

Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy
por: Groeneveldt, Christianne, et al.
Publicado: (2020)

Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning
por: Pol, Jonathan G, et al.
Publicado: (2020)

A recombinant oncolytic Newcastle virus expressing MIP-3α promotes systemic antitumor immunity
por: Huang, Feng-Ying, et al.
Publicado: (2020)

Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade
por: Jung, Bo-Kyeong, et al.
Publicado: (2020)

Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
por: Crespo-Rodriguez, Eva, et al.
Publicado: (2020)

Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies
por: Tselikas, Lambros, et al.
Publicado: (2020)

Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B
por: Alvarez de Cienfuegos, Ana, et al.
Publicado: (2020)

The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a
por: Peluso, Marisa O, et al.
Publicado: (2020)

A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth
por: Gleisner, María Alejandra, et al.
Publicado: (2020)

Oncolytic vesicular stomatitis virus–based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8(+) T-cell functionality
por: Niavarani, Seyedeh-Raheleh, et al.
Publicado: (2020)

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
por: Saha, Dipongkor, et al.
Publicado: (2020)

Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer
por: Lee, Yu Seong, et al.
Publicado: (2020)

IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
por: Chen, Tianyue, et al.
Publicado: (2021)

Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy
por: Muñoz, Nina M., et al.
Publicado: (2021)

Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory
por: Hinterberger, Maria, et al.
Publicado: (2021)

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
por: Ressler, Julia Maria, et al.
Publicado: (2021)

Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche
por: Müller, Louise M E, et al.
Publicado: (2021)

Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial
por: Zhang, Bo, et al.
Publicado: (2021)

Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma
por: Beasley, Georgia M, et al.
Publicado: (2021)

Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity
por: Yu, Xiaofei, et al.
Publicado: (2021)

Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
por: Allouchery, Marion, et al.
Publicado: (2020)

Neospora caninum: a new class of biopharmaceuticals in the therapeutic arsenal against cancer
por: Lantier, Louis, et al.
Publicado: (2020)

Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis
por: Gebremeskel, Simon, et al.
Publicado: (2021)

Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
por: Malvehy, Josep, et al.
Publicado: (2021)

New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models
por: Lopes, Alessandra, et al.
Publicado: (2021)

Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy
por: Khalique, Hena, et al.
Publicado: (2021)

T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A(+)CD141(+) cDC1 and CD14(+) antigen-presenting cell recruitment
por: Koster, Bas D, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d7eal335rsohivdm25tm65ads6